|
Targeted Genetics is putting the bull's-eye on disease. The drug developer is working in the promising (though as yet unproven) field of gene therapies, drugs that deliver particular DNA sequences into targeted cells to encourage (or sometimes inhibit) the production of proteins associated with disease. The company's drug candidates -- targeting conditions such as retinal dystrophies, lateral sclerosis, HIV/AIDS, heart failure, and Huntington's disease -- employ proprietary technology using bio-engineered viral cells (called vectors) to deliver the genes. The company is working on its own to develop therapies for certain candidates and with development partners on some other programs.
|
| | | Contact Information | |
Address: |
1100 Olive Way, Ste. 100
Seattle, WA 98101
| | Phone: | 206-623-7612 | | Fax: | 206-223-0288 |
|
| Financial
Highlights | | Fiscal Year End: | December | | Revenue (2008): | 8.70 M | | Revenue Growth (1 yr): | (-15.60%) | | Employees (2008): | 58 | | Employee Growth (1 yr): | (-20.50%) |
|
|
Key People
| | • |
Chairman:
Jeremy Curnock Cook
| | • |
President, CEO, and Director:
B. G. Susan Robinson
| | • |
VP Finance, CFO, and Treasurer:
David J. Poston
|
|
|
